ENTRADA THERAPEUTICS, INC. (TRDA) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -165.78M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-165.78M | (m) |
| 2026-03-31 | (m) | $-166.12M | (m) |
| 2025-12-31 | (m) | $-143.75M | (m) |
| 2025-09-30 | (m) | $-103.45M | (m) |
| 2025-06-30 | (m) | $-73.35M | (m) |
| 2025-03-31 | (m) | $24.78M | (m) |
| 2024-12-31 | (m) | $65.63M | (m) |
| 2024-09-30 | (m) | $54.95M | (m) |
| 2024-06-30 | (m) | $104.44M | (m) |
| 2024-03-31 | (m) | $23.48M | (m) |
| 2023-12-31 | (m) | $-6.68M | (m) |
| 2023-09-30 | (m) | $-21.77M | (m) |
| 2023-06-30 | (m) | $-82.37M | (m) |
| 2023-03-31 | (m) | $-79.62M | (m) |
| 2022-12-31 | (m) | $-94.62M | (m) |
| 2022-09-30 | (m) | $-88.43M | (m) |
| 2022-06-30 | (m) | $-77.73M | (m) |
| 2022-03-31 | (m) | $-64.45M | (m) |
| 2021-12-31 | (m) | $-51.16M | (m) |
| 2021-09-30 | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) |
| 2020-12-31 | (m) | $-26.52M | (m) |
| 2020-09-30 | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |